You are here: Industry Insights > Akorn

News List

Akorn Receives Product Approval (Ref: GlobeNewswire) firstwordpharma
November 27, 2018
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food
Fresenius focuses on data, computer lapses at Akorn in trial over $4.3B deal fiercepharma
July 27, 2018
A trial which will determine whether Germany’s Fresenius can cancel its $4.3 billion deal to buy out U.S. generics maker Akorn is focused on lapses in Akorn’s computer and data integrity.
Fresenius pulls out of $4.3bn Akorn merger pharmatimes
July 16, 2018
German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions.
Fresenius alleges ‘blatant fraud at the very top level’ of Akorn operations fiercepharma
May 08, 2018
Fresenius continues to hammer Akorn with allegations of fraud in its drug development and manufacturing as the German company battles to extract itself from its $4.3 billion buyout of the U.S. sterile injectables maker...
Fresenius pulls out of $4.3bn Akorn merger pharmatimes
April 24, 2018
German healthcare firm Fresenius Kabi is walking away from a $4.3-billion merger with US generics group Akorn, claiming that the latter has failed to fulfill several closing conditions.
Fresenius Kabi terminates $4.3-billion merger agreement with Akorn firstwordpharma
April 23, 2018
Fresenius Kabi announced Sunday that it has decided to abandon its planned takeover of Akorn, citing the latter's "failure to fulfill several closing conditions."
Akorn Shareholders Approve Merger Agreement with Fresenius Kabi americanpharmaceuticalreview
July 21, 2017
Akorn announced its shareholders have voted to approve the previously announced merger agreement providing for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.

Previous page 1 2 Next page